Brokers tip 4 ASX 200 healthcare shares to buy now

Healthcare is a defensive sector that can provide useful cover for investors when the market is volatile.

| More on:
A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

ASX 200 healthcare shares finished in the green on Tuesday, with the S&P/ASX 200 Health Care Index (ASX: XHJ) lifting 0.61%.

Healthcare is seen as a defensive sector.

In today's turbulent market, perhaps you might be looking for buying opportunities?

Here are four recommendations from the professionals.

ASX 200 healthcare shares that experts recommend

CSL Ltd (ASX: CSL)

Dylan Evans from Catapult Wealth has a buy rating on this ASX 200 biotech giant.

Evans told The Bull:

Threats from the Trump Administration to extend tariffs to imported pharmaceuticals would possibly have a negative impact on CSL, given it generates around half its revenue in the US.

Despite these risks, we believe CSL represents good value.

It remains a high quality company, delivering double digit earnings growth. It looks cheap compared to global peers.

The impact of US tariffs is factored into the share price, so, in our view, there's upside potential if they are withdrawn, or lower than anticipated.

CSL shares closed at $245.43 on Tuesday, up 0.47% today and down 10.8% over the past year.

Resmed CDI (ASX: RMD)

Jed Richards from Shaw and Partners says ASX 200 healthcare share, Resmed, is a buy.

He liked what he saw in the sleep apnoea device maker's latest report.

Richards said:

On April 24, ResMed posted an 8 per cent increase in revenue in the third quarter of fiscal year 2025. The gross margin improved 140 basis points to 59.3 per cent. Income from operations increased 14 per cent.

ResMed's innovative products and steady revenue growth make it a solid investment.

The Resmed share price closed at $36.75, down 0.49% on Tuesday and up 12.6% over the past year.

Healius Ltd (ASX: HLS)

John Athanasiou from Red Leaf Securities has a buy rating on diagnostic pathology and imaging company, Healius.

Athanasiou said:

The company is focusing on strengthening its core pathology operations.

Growth in test volumes, driven by an ageing population and increased demand for complex diagnostics, should support margin expansion — particularly as Healius invests in automation and artificial intelligence to reduce costs.

This ASX 200 healthcare share finished the session on Tuesday at $1.44, up 2.9% for the day and up 18.9% over the past 12 months.

Telix Pharmaceuticals Ltd (ASX: TLX)

Bell Potter has a buy rating on Telix Pharmaceuticals shares after the biotech reported strong revenue in the March quarter.

For the three months ended 31 March, Telix reported unaudited revenue of approximately US$186 million.

This was a 62% increase over the previous 12 months and a 31% bump over the December quarter.

The broker has a 12-month share price target of $36 on Telix Pharmaceuticals shares.

The ASX 200 healthcare share finished Tuesday's session at $26.95, up 1.01% for the day and up 74% over the year.

Motley Fool contributor Bronwyn Allen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, ResMed, and Telix Pharmaceuticals. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »